BOSTON--(EON: Enhanced Online News)--MetaStat, Inc. (OTCQB:MTST), a pre-commercial biotechnology company focused on the development and commercialization of diagnostic tests that are prognostic for risk of cancer metastasis, companion diagnostics to predict drug response, and anti-metastatic drugs, announced today that the Company will be presenting at the 9th Annual Biotech Showcase™ conference held in San Francisco from January 9th -11th at the Hilton San Francisco, Union Square.
Douglas A. Hamilton, Chief Executive Officer, will present an overview of the Company’s business and growth strategy on Monday, January 9, 2017 at 8:30 a.m. PST (11:30 a.m. EST) in Room 3 (Ballroom Level).
About MetaStat, Inc.
We are a pre-commercial biotechnology company focused on the development and commercialization of diagnostic tests that are prognostic for risk of cancer metastasis, companion diagnostics to predict drug response, and anti-metastatic drugs. Our driver-based platform technology is based on the pivotal role of the Mena protein and its isoforms, a common pathway for the development of metastatic disease in epithelial-based solid tumors.
Our product development strategy is based on identifying patients most at risk for cancer metastasis and targeting the underlying mechanisms that drive the metastatic cascade. Unlike most oncology therapeutics that kill cancer cells directly or inhibit cancer cell proliferation, we focus on preventing aggressive tumors from spreading.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.